Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
1991-5-28
|
| pubmed:abstractText |
Fourteen women, five with normal cervicovaginal mucosa (Group 1), five with cervical carcinoma (Group 2) and four with relapsing vulvovaginal candidiasis (Group 3) were enrolled and completed this open clinical trial. Each subject received a single dose of 1.82 +/- 0.3 g on average of vaginal paste (for ovules) containing about 1000 mg of 3H-fenticonazole nitrate (266 microCi). Twelve hours after vaginal administration, the paste was removed by vaginal washing. Blood, urine and stool samples were collected at specified time intervals for five days. Plasma, urine, stools and all used material in contact with the paste were assayed for radioactivity. No measurable levels of radioactivity were detected in plasma of subjects of Groups 1 and 3 while in 4 of the 5 subjects with cervical carcinoma (Group 2) fenticonazole was detected during the 24 h after administration with a peak level at about 8 hours. For a period of 5 days, 0.4-1.5% of the dose on average was recovered from urine, and 0.18-0.32% from feces. Based on the excretion data, the extent of vaginal absorption of fenticonazole nitrate in women with vulvovaginal candidiasis was 1.81 +/- 0.57% of the dose, while in women with normal cervicovaginal mucosa it accounted for 0.58 +/- 0.28% of the administered dose. In patients with cervical carcinoma, absorption was 1.12 +/- 0.53%. The maximum amount absorbed corresponds to an exposure of about 0.4 mg/kg of fenticonazole nitrate (for a subject weighing 50 kg). Consequently, the vaginal administration of one ovule containing 1000 mg of fenticonazole nitrate seems to be devoid of risk for patients.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
1120-009X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
3
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
23-7
|
| pubmed:dateRevised |
2009-8-4
|
| pubmed:meshHeading |
pubmed-meshheading:2019858-Absorption,
pubmed-meshheading:2019858-Administration, Intravaginal,
pubmed-meshheading:2019858-Adult,
pubmed-meshheading:2019858-Aged,
pubmed-meshheading:2019858-Antifungal Agents,
pubmed-meshheading:2019858-Candidiasis, Vulvovaginal,
pubmed-meshheading:2019858-Cervix Uteri,
pubmed-meshheading:2019858-Feces,
pubmed-meshheading:2019858-Female,
pubmed-meshheading:2019858-Humans,
pubmed-meshheading:2019858-Imidazoles,
pubmed-meshheading:2019858-Middle Aged,
pubmed-meshheading:2019858-Mucous Membrane,
pubmed-meshheading:2019858-Tritium,
pubmed-meshheading:2019858-Uterine Cervical Neoplasms,
pubmed-meshheading:2019858-Vagina
|
| pubmed:year |
1991
|
| pubmed:articleTitle |
Systemic absorption of 3H-fenticonazole after vaginal administration of 1 gram in patients.
|
| pubmed:affiliation |
Dept. of Pharmacology, University of Florence, Italy.
|
| pubmed:publicationType |
Journal Article
|